Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Dr. McMahon will provide a corporate overview, including a discussion ofthe development of picoplatin, the Company's lead product candidate.
A live audio webcast of the presentation will be available for 10 businessdays on the "Events" page of the "News & Events" section of the Company'swebsite at http://www.poniard.com.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused onthe development and commercialization of innovative oncology products toimpact the lives of people with cancer. Picoplatin, the Company's leadplatform product candidate, is a new generation platinum therapy with animproved safety profile relative to existing platinum-based cancer therapies.Picoplatin is designed to overcome platinum resistance associated withchemotherapy in solid tumors, and is being studied in multiple cancerindications, combinations and formulations. Clinical trials of intravenouspicoplatin include a Phase 3 trial in small cell lung cancer and Phase 2trials in metastatic colorectal and hormone-refractory prostate cancers, aswell as a clinical trial of oral picoplatin in solid tumors. Picoplatin hasnot been approved by any regulatory authority for use in humans. Foradditional information please visit http://www.poniard.com.
(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals,Inc.
SOURCE Poniard Pharmaceuticals, Inc.
You May Also Like